# Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary

> **NCT02590055** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 29 (estimated)

## Conditions studied

- Carcinoma of Unknown Primary

## Interventions

- **DRUG:** gemcitabine/docetaxel combination

## Key facts

- **NCT ID:** NCT02590055
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2018-09
- **Final completion:** 2019-09
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02590055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02590055, "Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02590055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*